Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netupitant/palonosetron - Helsinn

Drug Profile

Netupitant/palonosetron - Helsinn

Alternative Names: Akynzeo; Fosnetupitant/palonosetron; NEPA; NEPA - Helsinn; Palonosetron/Fosnetupitant; Palonosetron/netupitant

Latest Information Update: 18 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helsinn
  • Developer CJ HealthCare; Glenmark Pharmaceuticals Ltd; Helsinn; Mundipharma International; Purdue Pharma; Taiho Pharmaceutical; Vifor Pharma
  • Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 02 Aug 2019 Registered for Chemotherapy-induced nausea and vomiting (Prevention) in China (PO)
  • 31 May 2019 Safety and efficacy data from the a phase IIIb trial for Chemotherapy induced nausea and vomiting (Prevention) were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 06 Feb 2019 Launched for Chemotherapy-induced nausea and vomiting (Prevention) in France (PO) before February 2019 (NCT03831633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top